NCT02047110View on ClinicalTrials.gov

BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)

PHASE2CompletedINTERVENTIONAL

Enrollment

159

Participants

Timeline

Start Date

January 28, 2014

Primary Completion Date

March 5, 2015

Study Completion Date

July 25, 2016

Conditions

Ankylosing Spondylitis (AS)

Interventions

DRUG

placebo for risankizumab

Placebo for risankizumab administered by subcutaneous (SC) injection

DRUG

risankizumab

Risankizumab administered by subcutaneous (SC) injection

Sponsors

Lead Sponsor

Collaborators (1)

Boehringer Ingelheim

All Listed Sponsors

collaborator

Boehringer Ingelheim

INDUSTRY

lead

AbbVie

INDUSTRY